本文關(guān)鍵詞： 冠狀動脈慢血流 單核細胞數(shù)與高密度脂蛋白膽固醇比值 混雜因素　出處：《新疆醫(yī)科大學(xué)》2017年碩士論文　論文類型：學(xué)位論文

【摘要】：目的:探討血漿單核細胞數(shù)與高密度脂蛋白膽固醇比值(MHR)水平對冠狀動脈慢血流(SCF)發(fā)病的預(yù)測價值。方法:選擇2014年1月-2016年12月在我院心臟中心行冠狀動脈造影檢查顯示有慢血流現(xiàn)象但冠狀動脈未發(fā)現(xiàn)狹窄的患者457例(病例組),與同期因胸痛等不適就診,經(jīng)冠狀動脈造影檢查均未發(fā)現(xiàn)冠狀動脈狹窄,冠狀動脈無慢血流者503例(對照組)。檢測兩組外周血細胞計數(shù)及分類、空腹血糖、血脂、肝腎功能,并計算體重指數(shù)(body mass index BMI),MHR,血小板和淋巴結(jié)細胞比率(PLR),通過繪制ROC曲線判斷MHR預(yù)測SCF發(fā)病的臨界值,以臨界值為切點分組,分為低MHR組,高MHR,比較兩組臨床資料的差別,并行多元Logistic回歸分析SCF發(fā)病的危險因素。結(jié)果:病例組與對照組比較,年齡、體重、脈搏、平均血小板體積、肌酐、空腹血糖、甘油三酯、MHR、BMI兩組間差異均有統(tǒng)計學(xué)意義(P0.05);繪制ROC曲線獲得MHR切點為0.29,ROC曲線下的面積(AUC)0.561,P=0.001。多元Logistic回歸分析顯示年齡、男性、吸煙、高血壓、糖尿病、尿酸、MHR均是SCF的危險因素,高MHR組發(fā)生SCF的風(fēng)險是低MHR組的1.69倍,MHR(OR=1.69,CI 95%1.20-2.38,P0.01)。結(jié)論:MHR是SCF發(fā)病的獨立危險因素,MHR水平對SCF的發(fā)病有預(yù)測價值,隨MHR水平的增高,顯著增加SCF的發(fā)病風(fēng)險。
[Abstract]:Objective: to investigate the effect of plasma monocyte number and high density lipoprotein cholesterol ratio (MHRs) on coronary slow flow (SCF). Predictive value of morbidity. Methods:. Select 457 patients who underwent coronary angiography from January 2014 to December 2016 in the heart center of our hospital, which showed slow flow but no stenosis of coronary artery (. Case group). At the same time due to chest pain and other discomfort, no coronary artery stenosis was found by coronary angiography, and no slow flow of coronary artery was found in 503 cases (control group). Peripheral blood cell count and classification were detected in both groups. Fasting blood glucose, blood lipid, liver and kidney function, body mass index (BMI) and platelet and lymph node cell ratio (PLR) were calculated. The critical value of MHR for predicting the onset of SCF was determined by drawing ROC curve. The critical value was divided into two groups: low MHR group and high MHR group. The difference of clinical data between the two groups was compared. Results: age, body weight, pulse, mean platelet volume, creatinine, fasting blood glucose and triglyceride were compared between the case group and the control group. There was significant difference in MHRBMI between the two groups (P 0.05). ROC curve was drawn to obtain the area under the MHR cut point of 0.29 ROC curve. Multiple Logistic regression analysis showed that age was male. Smoking, hypertension, diabetes and uric acid were all risk factors of SCF. The risk of developing SCF in high MHR group was 1.69 times higher than that in low MHR group. ConclusionMHR is an independent risk factor for the pathogenesis of SCF. The level of MHR has predictive value in the pathogenesis of SCF. With the increase of MHR level, the risk of SCF increased significantly.
【學(xué)位授予單位】：新疆醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R543.3

【參考文獻】

相關(guān)期刊論文 前10條

1 郝云濤;邱春光;韓戰(zhàn)營;盧文杰;王徐樂;潘亮;;心率變異性與冠狀動脈慢血流相關(guān)性研究[J];醫(yī)學(xué)與哲學(xué)(B);2016年08期

2 黃文江;黃鶯;;冠狀動脈慢血流研究進展[J];醫(yī)學(xué)綜述;2016年14期

3 李楠;荊晶;劉昱圻;李泱;;冠狀動脈慢血流綜合征[J];臨床與病理雜志;2016年01期

4 張述良;張愛元;張孔源;黃一林;;冠狀動脈慢血流與冠狀動脈管腔特征的相關(guān)性研究[J];中國循環(huán)雜志;2015年12期

5 熊永紅;惠永明;;雙嘧達莫對冠狀動脈慢血流臨床療效研究[J];中國臨床醫(yī)生雜志;2015年05期

6 曾琪;余再新;丁建平;屈昌平;廖志雄;;冠狀動脈慢血流采用阿托伐他汀治療療效及對血脂影響分析[J];湖南師范大學(xué)學(xué)報(醫(yī)學(xué)版);2015年02期

7 劉篤秋;夏中華;潘迪華;蔡彬;周天天;;阿托伐他汀對冠狀動脈慢血流患者外周血內(nèi)皮祖細胞的作用[J];實用醫(yī)學(xué)雜志;2015年06期

8 王世勛;譚蕾;;麝香保心丸對冠狀動脈慢血流患者冠狀動脈血流速度和血清ET-1、hs-CRP水平的影響[J];山東醫(yī)藥;2015年09期

9 駱瑩瑩;陳述;王大新;;氧化應(yīng)激對動脈粥樣硬化內(nèi)皮細胞損傷作用的研究進展[J];醫(yī)學(xué)綜述;2015年05期

10 楊靖;叢曉亮;吳宗貴;;丹紅注射液治療冠狀動脈微血管功能障礙的研究[J];湖北中醫(yī)藥大學(xué)學(xué)報;2015年01期

，

本文編號：1472927